Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (977)	1/26/2000 1:29:00 PM
From: NeuroInvestment	Read Replies (3) \| Respond to of 1386

You are preaching to the choir. If you read my post carefully, it discusses the FDA's resistance to accepting ICP as a primary endpoint--they want functional outcome measures, showing that the variety of mechanisms presumed for HU211 affect patient functioning (cognitive, occupational, self-care,etc). You and I can agree that reducing ICP leads to an expected sequence of desirable events, and is thus a worthwhile endpoint in itself. But the FDA apparently does not agree. NeuroInvestment (www.neuroinvestment.com)